AI-generated analysis. Always verify with the original filing.
OS Therapies filed a prospectus supplement for the resale of up to 10,529,417 shares of common stock by selling stockholders, covering shares issuable upon warrant exercise and note conversion.
Event Type
Disclosure
Voluntary
Variant
8-K
.** **Other Events.** On March 31, 2026, OS Therapies Incorporated (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospect
Financial Statements and Exhibits.** (d) Exhibits. | Exhibit Number | | Description | |---|---|---| | 5.1 | | Opinion of Olshan Frome Wolosky LLP. | | 23.1 | |